Pixyl.Neuro.MS integrates into the routine workflow, to extract pertinent information on the size and location of Multiple Sclerosis (MS)-specific lesions, aimed at supporting the diagnosis and monitoring of patients. In case of multiple visits, the longitudinal analysis also provides data on the evolution of the lesions, and therefore on the activity of the disease with respect to diagnostic criteria. The software outputs both a quantitative report on lesion location, volume and evolution, as well as annotated MRI images with lesions labeled according to their evolution.
Product specifications Information source: Vendor
Last updated: Feb. 19, 2023
Product name Pixyl.Neuro.MS
Company Pixyl
Subspeciality Neuro
Modality MR
Disease targeted Multiple Sclerosis
Key-features Lesion detection, lesion quantification, lesion classification, lesional volume quantification, disease activity, longitudinal analysis, image annotation, McDonald MRI criteria
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion
After: diagnosis verification
Data characteristics
Population patients with known or suspected Multiple-Sclerosis
Input MR sequence, 3D T2-weighted FLAIR, 2D T2-weighted FLAIR, 3D T1-weighted (optional), 3D T1-weighted + contrast (optional)
Input format DICOM
Output structured report, color-coded segmentation overlay, table of quantified values
Output format PDF report, DICOM report, annotated DICOM sequences
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certified, Class IIa , MDD
No or not yet
Market presence
On market since 10-2019
Distribution channels Incepto, GE, Siemens, Brainomix, Osimis
Countries present (clinical, non-research use) >7
Paying clinical customers (institutes) >50
Research/test users (institutes) >50
Pricing model Subscription
Based on Number of installations, Number of analyses
Peer reviewed papers on performance

  • Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI (read)

Non-peer reviewed papers on performance

  • Leveraging 3d information in unsupervised brain mri segmentation (read)

  • Use of PIXYL software analysis of brain MRI (with & without contrast) as valuable metric in clinical trial tracking in study of multiple sclerosis (MS) and related neurodegenerative processes (read)

  • Use of Software Analytics of Brain MRI (with & without contrast) As Objective Metric in Neurological Disorders and Degenerative Diseases (read)

Other relevant papers